PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1865418
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1865418
According to Stratistics MRC, the Global Nutrigenomic Testing Kits Market is accounted for $66.9 million in 2025 and is expected to reach $183.6 million by 2032 growing at a CAGR of 15.5% during the forecast period. Nutrigenomic testing kits analyze an individual's genetic makeup to assess how their body responds to specific nutrients, dietary patterns, and lifestyle factors. By examining gene-nutrient interactions, these kits provide personalized insights into metabolism, food sensitivities, and nutrient absorption. The results help guide tailored nutrition and wellness strategies aimed at optimizing health outcomes. Typically used in preventive healthcare and personalized nutrition planning, nutrigenomic testing supports evidence-based dietary recommendations aligned with an individual's unique genetic profile and potential predispositions.
According to a 2020 review published in Nutrients (MDPI), the global direct-to-consumer nutrigenetic testing market was estimated to exceed 250 companies, with over 100 offering personalized dietary recommendations based on genetic profiles, reflecting rapid commercialization and growing consumer interest in gene-based nutrition strategies.
Consumers increasingly seeking DNA-based dietary recommendations
Individuals are increasingly turning to genetic profiling to understand nutrient metabolism, food sensitivities, and optimal diet plans tailored to their unique genetic makeup. This trend is further supported by the rise of health-conscious lifestyles and preventive care strategies. Digital platforms and mobile health apps are amplifying accessibility, allowing users to receive customized nutrition advice remotely. As awareness of gene-diet interactions expands, the market is witnessing a surge in consumer interest across both clinical and direct-to-consumer channels.
Limited clinical validation and standardization
Many kits rely on emerging research that has yet to be universally accepted by regulatory bodies or clinical practitioners. This ambiguity affects consumer confidence and limits integration into mainstream healthcare. Moreover, variations in testing methodologies and interpretation frameworks across providers create confusion and hinder comparability. Without robust clinical trials and consensus guidelines, the market risks being perceived as speculative rather than evidence-based.
Integration with preventive healthcare programs
Nutrigenomic testing is increasingly being positioned as a proactive tool within preventive healthcare frameworks. By identifying genetic predispositions to conditions like obesity, diabetes, and cardiovascular disease, these kits enable early dietary interventions that can mitigate long-term health risks. Healthcare providers and insurers are exploring partnerships to incorporate genetic nutrition screening into routine wellness programs. Additionally, corporate wellness initiatives and fitness platforms are adopting nutrigenomic insights to enhance personalized coaching and dietary planning.
Scientific skepticism and misinformation
Critics argue that many genetic-diet associations are still inconclusive or oversimplified, leading to potential misinformation. Inaccurate marketing claims and lack of transparency in test interpretation can erode consumer trust. Furthermore, the proliferation of unregulated DTC kits raises concerns about data accuracy and ethical use of genetic information. If not addressed through rigorous validation and clear communication, skepticism may slow market growth and regulatory acceptance.
The COVID-19 pandemic accelerated interest in home-based health monitoring, including genetic nutrition testing. With limited access to in-person consultations, consumers turned to remote diagnostics and personalized wellness tools. Nutrigenomic kits gained traction as individuals sought to optimize immunity and manage chronic conditions through tailored diets. However, supply chain disruptions and reduced laboratory capacity temporarily affected kit availability and turnaround times.
The whole exome/genome test kits segment is expected to be the largest during the forecast period
The whole exome/genome test kits segment is expected to account for the largest market share during the forecast period propelled by, its comprehensive genetic coverage and diagnostic depth. These kits analyze a broader range of genetic variants, enabling more detailed insights into nutrient metabolism, disease risk, and dietary response. Their application spans clinical nutrition, research, and personalized wellness, making them highly versatile. Technological advancements in sequencing and data interpretation are enhancing accuracy and affordability, further driving adoption.
The pharmacogenomics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the pharmacogenomics segment is predicted to witness the highest growth rate, influenced by, its role in optimizing drug-nutrient interactions. This segment focuses on how genetic variations influence individual responses to medications and supplements, enabling safer and more effective therapeutic plans. Rising interest in nutraceuticals and functional foods is fueling demand for pharmacogenomic insights that guide personalized supplementation. Integration with electronic health records and clinical decision support systems is also expanding its utility in healthcare settings.
During the forecast period, the North America region is expected to hold the largest market share, fuelled by, by robust healthcare infrastructure and high consumer awareness. The region benefits from early adoption of genetic technologies, strong presence of key market players, and favorable reimbursement policies. Regulatory clarity and widespread availability of DTC platforms have further accelerated market penetration. Additionally, rising prevalence of lifestyle-related disorders and growing interest in preventive nutrition are driving demand for personalized dietary solutions. Strategic collaborations between biotech firms and wellness providers continue to shape the regional landscape.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by, expanding healthcare access, rising disposable incomes, and growing interest in personalized wellness. Countries like China, India, and South Korea are witnessing increased adoption of genetic testing for nutrition and chronic disease management. Government initiatives promoting digital health and preventive care are creating fertile ground for market expansion. Local startups and international players are investing in culturally tailored nutrigenomic solutions, addressing diverse dietary habits and genetic profiles.
Key players in the market
Some of the key players in Nutrigenomic Testing Kits Market include 23andMe, AncestryDNA, Nutrigenomix, DayTwo, Genova Diagnostics, Quest Diagnostics, Invitae, Myriad Genetics, Helix, LifeDNA, Viome, Onegevity, Atlas Biomed, Coral Genomics, Pathway Genomics, Medichecks, Biotronik, NIPD Genetics, and Omixon.
In October 2025, AncestryDNA launched its biggest ethnicity update to date. The update added 68 new European regions and re-analyzed all user DNA for improved accuracy. It now connects users to over 3,600 global ancestral locations.
In September 2025, Nutrigenomix partnered with Evexia Diagnostics to expand access to personalized nutrition testing. Clinicians can now offer DNA-based dietary recommendations backed by peer-reviewed science.
In September 2025, Myriad partnered with SOPHiA GENETICS to develop a liquid biopsy companion diagnostic. This collaboration targets precision oncology using real-time genomic insights.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.